[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100418513":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":42,"responsibleParty":66,"collaborators":68,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":25,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":45,"whyStopped":25,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"LifeBridge Health","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Pericapsular Nerve Block Group","ACTIVE_COMPARATOR","Pericapsular Nerve Block targets the anterior hip capsule by blocking the articular branches of the femoral nerve and accessory obturator nerve.",[13],"Drug: Pericapsular Nerve Block",{"label":15,"type":10,"description":16,"interventionNames":17},"Fascia Iliaca Nerve Block Group","Fascia Iliaca Nerve Block targets the space between the iliacus muscle and the fascia that overlies it (fascia iliaca), within which the femoral nerve and lateral femoral cutaneous nerve (LFCN) course.",[18],"Drug: Fascia Iliaca Nerve Block",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Pericapsular Nerve Block","Per Standard Institutional Practice",[9],null,{"type":21,"name":27,"description":23,"armGroupLabels":28,"otherNames":25},"Fascia Iliaca Nerve Block",[15],[30],{"name":31,"affiliation":5,"role":32},"Ronald Delanois, MD","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Martin Gesheff","CONTACT","410-601-9467","mgesheff@lifebridgehealth.org",{"name":40,"role":36,"phone":25,"phoneExt":25,"email":41},"Nirav Patel","nirpatel@lifebridgehealth.org",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Sinai Hospital of Baltimore","RECRUITING","Baltimore","Maryland","21215","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-76.61219,39.29038,{"lat":55,"lon":54},[58,59,60,61,64],{"name":35,"role":36,"phone":25,"phoneExt":25,"email":38},{"name":40,"role":36,"phone":25,"phoneExt":25,"email":41},{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"name":62,"role":63,"phone":25,"phoneExt":25,"email":25},"James Nace, DO","SUB_INVESTIGATOR",{"name":65,"role":63,"phone":25,"phoneExt":25,"email":25},"Ethan Remily, DO",{"type":67,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[69],{"name":70,"class":71},"Rubin Institute for Advanced Orthopedics","UNKNOWN","100418513","phase-4-the-pericapsular-nerve-block-in-total-hip-arthroplasty-100418513",false,"NCT04729686","The Pericapsular Nerve Block in Total Hip Arthroplasty","The Pericapsular Nerve Block in Total Hip Arthroplasty: A Randomized, Controlled Trial","PENG","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Planned primary total hip arthroplasty with anterior (Smith-Peterson) approach\n* ASA score of 1 to 3\n* Indicated for one of the two nerve block groups\n* Must be opioid naïve at screening as defined by the FDA - According to the Food and Drug Administration, opioid-tolerant patients were those currently receiving or who had previously received 60 mg PO morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg PO oxycodone per day, 8 mg PO hydromorphone per day, 25 mg PO oxymorphone per day, 60 mg PO hydrocodone per day, or an equivalent dose of another opioid for a duration of one week or longer (16)\n\nExclusion Criteria:\n\n* Current or previous diagnosis of \"chronic pain\"\n* Opioid tolerant at time of screening (for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid.)\n* Diagnosis of ankylosing spondylitis\n* Allergy to any potential medications utilized in any of the two groups\n* Conversion of patient to general anesthesia intraoperatively\n* Treatment with another investigational drug or other intervention for pain\n* Any condition(s) or diagnosis, both physical or psychological, or physical exam finding in the opinion of the investigator that would precludes participation","ALL","18 Years","80 Years",{"count":84,"type":85},78,"ESTIMATED","INTERVENTIONAL",[88],"PHASE4","In order to continue progressing towards outpatient total hip arthroplasty (THA), methods to adequately manage postoperative pain is of paramount importance. The purpose of this study is to quantify the effectiveness of the pericapsular nerve block in total hip arthroplasty in comparison to the fascia iliaca nerve block.",[91,92],"Hip Osteoarthritis","Hip Arthropathy",[94,95,96,97,98],"Total Hip Arthroplasty","Total Hip Replacement","Hip Arthroplasty","Hip Replacement","Postoperative Pain","2025-01-20",{"date":101,"type":102},"2025-01-22","ACTUAL",{"date":104,"type":102},"2020-12-09",{"date":106,"type":85},"2025-12-01",{"name":5,"class":6},1]